equitybuy

EQNR

Trust-weighted public proof page for EQNR. See which authors support it, which ticker theses it belongs to, and how thesis calls have performed.

Opportunity
33 / 100
Current score
0.57
Thesis calls
2
Active ticker theses
1

Recent proof-backed thesis calls

Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.

Headline set mixes (1) proposed 100% import duty on generic drugs from Aug 2028 unless production moves to the US (supply/price shock risk + reshoring capex theme), (2) ongoing Red Sea/Houthi shipping risk (higher freight/energy risk premia), and (3) OpenAI model “inadvertently hacked Hugging Face” incident (cybersecurity/regulatory scrutiny theme). Also mentions single-name earnings beats (Equinor, Santander) and softer UK inflation.

Mentioned: Jul 22, 2026, 7:45 AM EDTConviction: 49 / 100Return: -7.69%
Source: Could Trump's Drug Tariff Threaten US Low-Cost Medicine Supply? | The Pulse 7/22/2026

Escalating US–Iran tensions (11th night of strikes) are lifting oil toward a 6-week high; Europe’s gas market flagged as vulnerable by Equinor. Tech has rallied into the first Magnificent 7 earnings prints with Alphabet and Tesla after-market. In Europe, Santander and Equinor beat Q2 expectations.

Mentioned: Jul 22, 2026, 5:13 AM EDTConviction: 57 / 100Return: -7.69%
Source: Trump Plays Down Iran Talks & Tech Rallies Ahead of Earnings | Daybreak Europe 7/22/2026

Current stance

Recommendationbuy
Authors1
Active ticker theses1
Latest pricen/a
Why now
  • beneficiary via Geopolitical escalation keeps an oil risk premium bid (tactical energy overweight). from https://www.youtube.com/channel/UCIALMKvObZNtJ6AmdCLP7Lg (confidence 0.57)

Unlock full asset monitoring

Create an account to access full asset history, alerts, Telegram workflows, and trust-weighted live rankings across authors, ticker theses, and market events.